•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.2 Overlooked Oil Stocks to Buy Now Before They Soar
M&S buys mothballed fulfilment centre from Asos for £67m
3 Small-Cap Stocks to Buy Before May 15
Ardmore Shipping Q1 Earnings Call Highlights
Ardmore Shipping: Doubling The Payout Turns It Into A Buy (Ratings Upgrade)
Ardmore Shipping Corporation (ASC) Q1 2026 Earnings Call Transcript
Ardmore Shipping Corporation Announces Financial Results For The Three Months Ended March 31, 2026
Ardmore Shipping Announces First Quarter 2026 Conference Call and Webcast
Ardmore Shipping Provides Update on Fleet Investment, Dividend Policy, and Vessel Sale
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
Asos climbs as profit margins show improvement, with analysts wanting more stability
A Look at Ardmore Shipping Corp (ASC) After 4.8% Gain -- GF Value $9.16 vs Price $16.24
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Ardmore Shipping Files 2025 Annual Report on Form 20-F
Brokerages Set Ardmore Shipping Corporation (NYSE:ASC) Target Price at $13.67
Ardmore Shipping Corporation (ASC) Analyst/Investor Day Transcript
Ardmore Shipping Corporation Announces Financial Results For The Three and Twelve Months Ended December 31, 2025
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne